Abstract |
Emerging evidence has shown the role of mesenchymal stem cell-derived exosome (MSC-exo) in inducing resistance of cancer cells to chemotherapy. However, it remains unclear whether the change of MSC-exo in response to chemotherapy also contributes to chemoresistance. In this study, we investigated the effect of a standard-of-care chemotherapeutic agent, doxorubicin (Dox), on MSC-exo and its contribution to the development of Dox resistance in breast cancer cells (BCs). We found that the exosome secreted by Dox-treated MSCs (Dt-MSC-exo) induced a higher degree of Dox resistance in BCs when compared with non-treated MSC-exo. By analysis of the MSC-exo-induced transcriptome change in BCs, we identified S100A6, a chemoresistant gene, as a top-ranked gene induced by MSC-exo in BCs, which was further enhanced by Dt-MSC-exo. Furthermore, we found that Dox induced the expression of miR-21-5p in MSCs and MSC-exo, which was required for the expression of S100A6 in BCs. Importantly, silencing of miR-21-5p expression in MSCs and MSC-exo abolished the resistance of BCs to Dox, indicating an exosomal miR-21-5p-regulated S100A6 in chemoresistance. Our study thus uncovered a novel mechanistic insight into the role of MSC-secreted exosome in the development of chemoresistance in the tumor microenvironment.
|
Authors | Tao Luo, Qiaoyuan Liu, Aihua Tan, Lixia Duan, Yuxian Jia, Li Nong, Jing Tang, Wenxian Zhou, Weimin Xie, Yongkui Lu, Qiang Yu, Yan Liu |
Journal | Molecular therapy oncolytics
(Mol Ther Oncolytics)
Vol. 19
Pg. 283-293
(Dec 16 2020)
ISSN: 2372-7705 [Print] United States |
PMID | 33294586
(Publication Type: Journal Article)
|
Copyright | © 2020 The Author(s). |